

Functional Angioplasty

Insight from FFR and IVUS

Seung-Jung Park, MD, PhD

Professor of Medicine, University of Ulsan College of Medicine,
Heart Institute, Asan Medical Center, Seoul, Korea

New Insight for FFR vs. IVUS

Epicardial Artery

FFR and IVUS MLA

IVUS guided optimization

In Epicardial Artery

Published IVUS MLA Cut-off Value





	Nishioka T, JACC 1999	Briguori et al AJC 2001	Takaki et al Cir. 1999	Abizaid et al AJC 1998
	70 lesions	53 lesions	42 pts	86 pts
Cut-off of MLA (mm²)	<4.0 (Thallium +)	< 4.0 (FFR<0.75)	<3.0 (FFR<0.75)	> 4.0 (CFR >2.0)
Sensitivity	80%	92%	83 %	Accuracy
Specificity	90%	54%	92.3 %	92%
QCA VD (mm)		3.08±0.3		
DS (%)		52±11		
MLA (mm²)	3.3±2.3	3.9±2.5	3.9±2.0	4.4±2.0
MVA (mm²)		12.0±4.6		13.2±4.4
Area stenosis%		65±18	55±24	43±24

Published Data Review

New Comparison

AMC prospective cohort registry, (n=236 lesions)

FFR vs.
IVUS MLA



Multivariable Analysis to Predict FFR

Independent predictors for FFR <0.08


Age (OR=0.238, 95% CI=0.090-0.629, p=0.003),

MLA (OR=0.206, 95% CI=0.100-0.424, p<0.001),

Plaque burden (OR=1.062, 95% CI=1.014-1.111, p=0.010),

LAD location (OR=4.371, 95% CI=0.755-10.885, p=0.002).


New IVUS MLA matched with FFR <0.80 (n=236)





2.42mm²
AUC=0.800,
95% CI=0.742-0.848

Sensitivity=90%
Specificity=60%
PPV=37%
NPV=96%
Accuracy=68%

In total 692 consecutive patients with 784 coronary lesions were assessed by IVUS and FFR before intervention




MLA Criteria to Predict FFR<0.80




Sensitivity 84%
Specificity 63%
PPV 48%
NPV 90%

LAD (n=528)




Sensitivity 80%, Specificity 64%

LCX (n=68)




Sensitivity 89%, Specificity 77%

RCA (n=188)




Sensitivity 79%, Specificity 77%

Plaque rupture (n=51)




Sensitivity 69%, Specificity 55%

Diabetes (n=249)




Sensitivity 86%, Specificity 65%

ACS (n=193)




Sensitivity 71%, Specificity 75%

RLD <2.75mm (n=184)




Sensitivity 64% Specificity 69%

RLD 2.75–3.5mm (n=439)




Sensitivity 80% Specificity 68%

RLD >3.5mm (n=161)




Sensitivity 89% Specificity 65%

Proximal (n=285)




Sensitivity 78% Specificity 68%

Mid (n=405)




Sensitivity 84% Specificity 65%

Distal (n=94)




Sensitivity 76% Specificity 70%

Proximal LAD (n=180)




Sensitivity 79% Specificity 70%

Mid-LAD (n=323)




Sensitivity 85% Specificity 61%

Distal LAD (n=25)




Sensitivity 80% Specificity 93%

Proximal, non-LAD (n=105)




Sensitivity 73% Specificity 77%

Mid, non-LAD (n=82)



Sensitivity 82% Specificity 79%

Distal, non-LAD (n=69)



Sensitivity 75% Specificity 64%


New IVUS MLA
matched with FFR <0.80

2.4 mm²

Kang SJ, Park SJ, Circ Cardiovasc Interv. 2011;4: 65-71

32%

Decision making (treat or not treat) should be done by FFR not by IVUS MLA.



2.4 mm² 4 mm²


IVUS guided Stent Optimization

IVUS Predictors for Clinical Outcomes

IVUS stent CSA and total stent length,
are independent predictors for
restenosis and stent thrombosis.

Park, DW. AJC 2006;98:353-356, AMC data
Hong MK, Eur Heart J, 2006;27:1305, AMC data
Suh J, JACC Intv, 2010;3:383-9


Optimal IVUS **Stent CSA** to Predict Restenosis (n=541, **SES**)



Cut-off value
5.5 mm²

Sensitivity 72.2%
Specificity 66.3%
(AUC 0.74)


Optimal IVUS **Stent CSA** to Predict Restenosis (n=220, **ZES**)



Cut-off value
5.3 mm²

Sensitivity 56.7%
Specificity 61.8%
(AUC 0.67)

Optimal IVUS Stent CSA to Predict Restenosis (n=229, EES)



Cut-off value
5.4 mm²

Sensitivity 60.0%
Specificity 59.9%
(AUC 0.64)

IVUS Guided Stent Optimization (Rule of 5)

Stent CSA : > 5.5 mm²

Stented length : < 50 mm

< 2 % TVR

Park, DW. AJC 2006;98:353-356,
Hong MK, Eur Heart J, 2006;27:1305,AMC data

Left Main Disease


FFR and IVUS MLA

IVUS guided optimization

FFR vs. Angiography

Mismatch


in intermediate LM Disease



Hamilos M, Circulation 2009; 120: 1505-1512


Mismatch

in Isolated intermediate LM Disease (n=55)



Different Insight for FFR vs. IVUS in Left Main Disease

IVUS MLA $< 6.0 \text{ mm}^2$ is matched with FFR < 0.75



New Comparison

AMC prospective cohort registry
(n=55 lesions), 2011


FFR vs.
IVUS MLA

Preliminary Data, 2011


New IVUS MLA

AMC prospective cohort registry (n=55 lesions)

C. MLA predicting FFR<0.75



A. MLA predicting FFR<0.80



4.1 mm²

4.8 mm²

New IVUS MLA


Matched with FFR <0.80 in LM Disease

4.8 mm²

Preliminary AMC data

FFR > 0.8

FFR < 0.8



Sensitivity 89%
Specificity 83%
PPV 82%
NPV 89%
Accuracy 86%

● Plaque rupture
○ No rupture

MLA mm²


MLA 6.0 mm²

MLA 4.8 mm²

In Epicardial artery

FFR > 0.8

FFR < 0.8



2.4 mm²

New IVUS MLA (4.8 mm²)
can predict functional
significance of stenosis of
LM disease. (PPV : 82%)

In Real Practice

Ostial and Shaft LM PCI

- **Functional Assessment (FFR)** is Crucial.
- **Just Stent it !** It takes just 5 minutes !
- We have more than 5 -10 year long-term data.
- No difference of death and MI compared with surgery (even better).
- Long-term clinical outcomes should be comparable to 100% of arterial grafts.

Distal LM Bifurcation Treatment


Still FFR-guided decision making for intermediate lesion, IVUS-guided lesion specific approach, and IVUS-guided optimization.

IVUS guided Stent Optimization

IVUS *Stent Area* and its Impact for restenosis in 403 Patients with Unprotected Left Main Disease

All patients treated with SES
100% Post-stent IVUS,
100% Angiography F/U at 9 months and
2 years clinical F/U

IVUS Measurement




POC : Polygon Of Confluence





Restenosis at 2 year

Ostial and Shaft

Bifurcation PCI




Minimal Stent Area (mm²) to predict ISR



Specificity

IVUS Stent Optimization (Stent Cross-sectional Area)



Take Home Message

FFR and IVUS MLA ,
they are totally different.

FFR, When ?

If the patient have no data about the non-invasive stress tests,

Please consider FFR in the cath. Lab !

FFR, When ?

Angiographic (visual) DS <80%
(60% of your procedures) should be
considered FFR.

60% out of them would be negative
FFR.

IVUS, When ?

IVUS guidance have **more understanding** about inside of the vessel (ostial lesion assessment, negative remodeling, plaque characterization and true reference vessel size).

IVUS, When ?

Absolute lumen CSA $>2.4 \text{ mm}^2$ in epicardial artery is well matched with negative FFR (NPV 90%) and we also have **IVUS criteria** (IVUS MLA $>5 \text{ mm}^2$) to minimize TLR .

Absolute lumen CSA $<4.8 \text{ mm}^2$ is the suggested criterion for intervention and we also have **IVUS criteria** (IVUS MLA 5,6,7,8 mm^2) to minimize TLR for LM disease PCI.

Issue is,

Do you want to treat the **Lesion** ?
based on angiography or IVUS MLA

Do you want to treat the **Patient** ?
based on FFR
and/or non-invasive stress test